Further markers of NMJ stability, notably brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF) have been assessed and a reduction in the levels of both have been associated with muscle loss and sarcopenia in Parkinson’s disease patients [46]. This evidence concerns the gene GDNF and sarcopenia.